SCHEMBL10044527

SCHEMBL10044527

CCOC(=O)Nc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Cl)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 7/20 0.72
MEN1 O00255 6/20 0.65
KMT2A Q03164 6/20 0.65
ALDH1A1 P00352 7/20 0.59
POLB P06746 1/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
LMNA P02545 1/20 0.59
RECQL P46063 1/20 0.59
HSD17B10 Q99714 1/20 0.59
KDM4E B2RXH2 6/20 0.58
NPSR1 Q6W5P4 2/20 0.58
HTT P42858 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
USP2 O75604 1/20 0.56
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
TSHR P16473 1/20 0.55
CYP2C19 P33261 1/20 0.55
TTR P02766 1/20 0.53
HPGD P15428 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10044528 0.84 RXFP1 (1.00) RXFP1MEN1KMT2AALDH1A1POLB
SCHEMBL3582133 0.83 RXFP1 (0.72) RXFP1MEN1KMT2AALDH1A1POLB
SCHEMBL15199240 0.81 PIK3CD (0.68) MEN1KMT2AALDH1A1POLBSMN1; SMN2
SCHEMBL3625455 0.80 RXFP1 (0.72) RXFP1MEN1KMT2AALDH1A1POLB
SCHEMBL27793516 0.79 ALDH1A1 (0.74) RXFP1MEN1KMT2AALDH1A1POLB
SCHEMBL2302031 0.78 ALDH1A1 (0.78) RXFP1MEN1KMT2AALDH1A1POLB
SCHEMBL2301933 0.77 ALDH1A1 (0.67) RXFP1MEN1KMT2AALDH1A1POLB
SCHEMBL2302494 0.77 RXFP1 (0.73) RXFP1MEN1KMT2AALDH1A1POLB
SCHEMBL3832220 0.76 RXFP1 (0.78) RXFP1MEN1KMT2AALDH1A1POLB
SCHEMBL189608 0.76 ALDH1A1 (1.00) RXFP1MEN1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130211076-A1 Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides MERCK SERONO S.A. GENEVA (CH) 2013-08-15 US disclosed
WO-2012052420-A1 METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES MERCK SERONO S.A. GENEVA (CH) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130211076-A1 Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides STS, NQO2, ASNS RXFP1 3539/4885MEN1 1802/4885KMT2A 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.